⌘K
Loading ticker…
As of 2026-08-24, Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) has a 3-month relative strength percentile of 34 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 70. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.1%, relative volume 0.85×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
ZNTL is held by 3 ETFs as of May 2026. Top owner: VHT at 0.00% weight, $602K notional. Top 3 carry $1M.
Held by 10 ETFs · $8M across latest filings · largest weight 0.11% (FSCC).
Top 3 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.00% | $602K | — |
| FSCC | 0.11% | $317K | +0.04 pp |
| AVSC | 0.01% | $313K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ZNTL Jan avg: 8.21% median: -2.30% win: 50% σ: 53.89% n: 4 2022-04-12 → 2026-07-31 | ZNTL Feb avg: 5.84% median: 8.66% win: 50% σ: 20.69% n: 4 2022-04-12 → 2026-07-31 | ZNTL Mar avg: -7.18% median: -5.62% win: 25% σ: 12.27% n: 4 2022-04-12 → 2026-07-31 | ZNTL Apr avg: 8.78% median: -10.69% win: 40% σ: 41.01% n: 5 2022-04-12 → 2026-07-31 | ZNTL May avg: 0.30% median: -0.25% win: 40% σ: 13.11% n: 5 2022-04-12 → 2026-07-31 | ZNTL Jun avg: -4.71% median: 8.33% win: 60% σ: 35.36% n: 5 2022-04-12 → 2026-07-31 | ZNTL Jul avg: 2.08% median: -2.27% win: 40% σ: 10.13% n: 5 2022-04-12 → 2026-07-31 | ZNTL Aug avg: 0.73% median: -4.37% win: 25% σ: 15.13% n: 4 2022-04-12 → 2026-07-31 (current) | ZNTL Sep avg: -12.07% median: -14.93% win: 25% σ: 13.36% n: 4 2022-04-12 → 2026-07-31 | ZNTL Oct avg: -7.27% median: -9.55% win: 25% σ: 18.68% n: 4 2022-04-12 → 2026-07-31 | ZNTL Nov avg: -3.88% median: -8.25% win: 25% σ: 26.56% n: 4 2022-04-12 → 2026-07-31 | ZNTL Dec avg: 1.01% median: -7.27% win: 25% σ: 22.86% n: 4 2022-04-12 → 2026-07-31 |